Vor Biopharma (VOR) Cash from Financing Activities (2020 - 2026)

Vor Biopharma (VOR) has reported Cash from Financing Activities for 7 consecutive years, with $74.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 12454.79% year-over-year to $74.9 million; the TTM figure through Mar 2026 stood at $579.3 million (up 999.42% YoY), while the FY2025 annual figure was $503.8 million, up 843.6% from the prior year.
• Cash from Financing Activities fell to $74.9 million in Q1 2026 per VOR's latest filing, from $307.8 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $307.8 million in Q4 2025 and bottomed at -$606000.0 in Q1 2025.
• Historically, Cash from Financing Activities has averaged $44.2 million across 5 years, with a median of $604000.0 in 2022.
• On a YoY basis, Cash from Financing Activities climbed as much as 564825.81% in 2025 and fell as far as 731.25% in 2025.
• Vor Biopharma's Cash from Financing Activities stood at $112.3 million in 2022, then tumbled by 99.98% to $25000.0 in 2023, then surged by 213044.0% to $53.3 million in 2024, then jumped by 477.64% to $307.8 million in 2025, then slumped by 75.68% to $74.9 million in 2026.
• Business Quant data shows VOR's Cash from Financing Activities at $74.9 million in Q1 2026, $307.8 million in Q4 2025, and $21.5 million in Q3 2025.